Medical experts come together to share their views in this on-demand webinar replay of an interactive online discussion:

Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch.

 

  • The independent expert panel examined the outcomes of patients with hepatocellular carcinoma (HCC) who underwent first-line immunotherapy (IO) and discussed clinical considerations for switching treatment
  • They also covered treatment options for patients with HCC who are not eligible for IO in 1st line, the data supporting 2nd line treatment options, and how to achieve optimal sequencing
  • The event concluded with speakers and participants engaging in a Q&A to address pressing questions

 

Watch the replay, divided into 4 digestible videos below, download the accompanying slides, and take the accredited e-learning using the blue button below the videos.


Clinical Takeaways

  • A substantial part of the advanced HCC patient population is not eligible for IO 1st line, such as:

    • Post-liver transplant patients with recurrent HCC

    • Most patients with an active autoimmune disease

  • TKIs, such as lenvatinib and sorafenib, are recommended treatments for these patient groups

  • Switching to 2nd line after IO 1st line should be considered in case of toxicity or disease progression

    • Measuring disease progression can be challenging, as there are several methods with different evaluation criteria

    • mRECIST criteria have a powerful ability to discriminate between responders and non-responders

  • Multiple 2nd line treatment options have been approved in advanced HCC patients

    • There is a lack of solid evidence for optimal 2nd line regimens after progression on new standard 1st line IO-based combination therapy

 

Meeting Chair: Prof. Michel Ducreux

Co-chairs: Dr Timon Vandamme and Assoc. Prof. Changhoon Yoo

This event is brought to you in collaboration with HCC CONNECT, a group of independent international experts specialising in liver oncology.

 

This programme is endorsed by:

 

 

Digestive Cancers Europe (DiCE) is the European umbrella organisation of a large group of national members representing patients with digestive cancer – colorectal, gastric, liver, oesophageal, pancreatic and rare cancers. Our mission is to contribute to early diagnosis and decreased mortality from digestive cancers and to increase overall survival and quality of life.

DiCE is running a survey to map the availability of liver cancer treatments across the EU. The aim is to aid broader access to best-practice care to ultimately increase liver cancer survival rates across Europe. Can you spare 15 minutes to share what treatments are available in your EU country? Take the survey.

Timon Vandamme is a Senior Consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital. As a clinician-researcher, he is performing research in circulating cell-free DNA (ccfDNA) in digestive and neuroendocrine neoplasms.

 

Dr Vandamme obtained a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, the Netherlands, on preclinical and translation evaluation of everolimus resistance and pancreatic NET genomics. His PhD project has led to multiple publications in peer-reviewed journals and received numerous awards, both national and international. Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp.

 

Furthermore, he is the Principal Investigator (PI) of > 10 trials at the University Hospital Antwerp, both industry-sponsored and academic trials. He is promotor of four PhD students and mentor of two additional PhD students. He has authored numerous papers outside his PhD in journals such as Clinical Cancer Research and Lancet Oncology. He has peer-reviewed for different high-impact journals and is a member of the editorial board of Endocrine-Related Cancer.

He is currently acting secretary of the Dutch Belgian Neuroendocrine Tumor Society (DBNETS) and co-opted board member of the Belgian Group of Digestive Oncology (BGDO).

 

Dr Changhoon Yoo is a medical oncologist who specialises in the care of patients with gastrointestinal cancers including hepatocellular carcinoma. He is an Assistant Professor at Asan Medical Center in Seoul, South Korea. Dr Yoo obtained his medical degree at the University of Ulsan College of Medicine, Seoul, South Korea and completed post graduate training at Asan Medical Center. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with hepatocellular carcinoma. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatocellular carcinoma. Relevant publications Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018 Aug 23; pii: S0016-5085(18)34897-2. doi: 10.1053/j.gastro.2018.08.030. [Epub ahead of print] PMID: 30145359 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print] PMID: 29898591 
Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. Int J Biol Markers 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print] PMID: 29874985 
Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018 Jun;36(3):496-502. doi: 10.1007/s10637-017-0548-7. Epub 2017 Dec 1. PMID: 29192354 Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.

Asst. Prof. Changhoon Yoo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Eisai, MSD, Ono and Ipsen.

Programme summary
Take the e-learning now
Other episodes of this series
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

of

episode
  • clock 19 MIN
  • calendar Jul 2024

this xxx bayer
conference-update Conference update
Oncology 
ASCO 2024 highlights

Experts
Prof. Shaheenah Dawood
Endorsed by
Bayer
  • download Downloadable
    Resources
  • clock 03 MIN
  • calendar Jul 2024

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis
  • download Downloadable
    Resources
  • clock 14 MIN
  • calendar Sep 2023

Brought to you by COR2ED Medical Affairs in collaboration with Viatris.
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer

An interactive patient case video series from breast cancer specialists

Experts
Dr Elisa Agostinetto, Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
publication Publication
Oncology  Patient Support
Surveillance and Diagnosis of HCC in Asia: Poster Presentation at ILCA 2023

Data from an Asia-Pacific patient and HCP survey

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Roche.
video Video
Oncology 
Long-term Response in Advanced Colorectal Cancer

A video update from Prof. Gerald Prager

Experts
Assoc. Prof. Gerald Prager
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Bayer.